Controlling T cell exhaustion in cancer treatment

Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer

NIH-funded research Sloan-Kettering Inst Can Research · NIH-11072059

This study is looking at how special immune cells affect the tiredness of important cancer-fighting cells, called CD8+ T cells, and aims to find ways to help these T cells work better in fighting cancer, which could lead to better treatments for patients.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionSloan-Kettering Inst Can Research NIH-funded
Lab location1 site (New York, United States)
Project IDNIH-11072059 on NIH RePORTER

What this research studies

This research investigates how certain immune cells, called antigen-presenting cells, influence the exhaustion of CD8+ T cells, which are crucial for fighting cancer. The study focuses on understanding the mechanisms that lead to T cell dysfunction in the tumor environment and explores potential therapeutic interventions to revive these exhausted T cells. By analyzing the role of tumor-associated macrophages and their ability to present cancer antigens, the research aims to identify new strategies to enhance anti-cancer immunity. Patients may benefit from insights that could lead to improved immunotherapy treatments.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients with cancers that exhibit T cell exhaustion and who are undergoing or considering immunotherapy.

Not a fit: Patients with early-stage cancers or those whose immune systems are not significantly affected may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that restore the function of exhausted T cells.

How similar studies have performed: Previous research has shown promise in using immune checkpoint blockade therapies to revive exhausted T cells, indicating that this approach may lead to significant advancements in cancer treatment.

Where this research is happening

New York, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer immunotherapy
Last reviewed 2026-06-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.